Company intelligence / Profile preview

PreemptiveAI

Seattle, Washington, United Statespreemptiveai.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

PreemptiveAI has developed a large-scale foundation model that interprets biomedical signals from wearables and smartphones to map human physiology in real time. The technology is designed for early disease detection, health risk prediction, remote patient monitoring, and personalized intervention. Initial deployments are planned for 2024 with strategic partnerships in place.

Modalities: Device (wearables, smartphones)Software as a Medical Device (SaMD)
Industry: Physiological Monitoring

Partnerships

Duke University (strategic partnership focused on predictive analytics for hospital readmissions and rising health risks)

Beyond the preview

Go deeper on PreemptiveAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreemptiveAI.

Explore the full profile